Mind + Muscle

technical minds + legal muscle


dig deep

Idenix Seen As Unlikely to Prevail Against Gilead in HCV Patent Interference

  • 04.11.13
  • Christine Livoti and Anusha Kambhampaty
  • Biopharm Insight

Deborah Sterling is quoted in a BioPharm Insight article about Idenix Pharmaceuticals' patent interference against Gilead Sciences. A recent decision designated Idenix as the junior party and Gilead as the senior party, placing the burden of proof in the proceeding on the former.

Sterling says, "If Idenix can prove an earlier actual reduction to practice, or an earlier conception coupled with diligence over the critical period, it could prevail."

Related People

Related Services

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.